1
|
Zhang X, Huo X, Guo H, Xue L. Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges. Front Pharmacol 2022; 13:965244. [PMID: 36263120 PMCID: PMC9574044 DOI: 10.3389/fphar.2022.965244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 09/14/2022] [Indexed: 11/13/2022] Open
Abstract
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical practice. However, more than 40% of patients with BRCA1/2 mutations are insensitive to PARP inhibitors, which has aroused attention to the mechanism of PARP resistance and sensitization schemes. PARP inhibitor resistance is related to homologous recombination repair, stability of DNA replication forks, PARylation and epigenetic modification. Studies on epigenetics have become the hotspots of research on PARP inhibitor resistance. As an important epigenetic regulator of transcription mediated by histone methylation, EZH2 interacts with PARP through DNA homologous recombination, DNA replication, posttranslational modification, tumor immunity and other aspects. EZH2 inhibitors have been just shifting from the bench to the bedside, but the combination scheme in cancer therapy has not been fully explored yet. Recently, a revolutionary drug design combining PARP inhibitors and EZH2 inhibitors based on PROTAC techniques has shed light on the resolution of PARP inhibitor resistance. This review summarizes the interactions between EZH2 and PARP, suggests the potential PARP inhibitor sensitization effect of EZH2 inhibitors, and further discusses the potential populations that benefit from the combination of EZH2 inhibitors and PARP inhibitors.
Collapse
Affiliation(s)
- Xi Zhang
- Department of Obstetrics and Gynecology, Peking University Third Hospital, Haidian, China
| | - Xiao Huo
- Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Haidian, China
- Biobank, Peking University Third Hospital, Haidian, China
| | - Hongyan Guo
- Department of Obstetrics and Gynecology, Peking University Third Hospital, Haidian, China
- *Correspondence: Lixiang Xue, ; Hongyan Guo,
| | - Lixiang Xue
- Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Haidian, China
- Biobank, Peking University Third Hospital, Haidian, China
- *Correspondence: Lixiang Xue, ; Hongyan Guo,
| |
Collapse
|
2
|
Kumar V, Kumar A, Mir KUI, Yadav V, Chauhan SS. Pleiotropic role of PARP1: an overview. 3 Biotech 2022; 12:3. [PMID: 34926116 PMCID: PMC8643375 DOI: 10.1007/s13205-021-03038-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Accepted: 10/20/2021] [Indexed: 01/03/2023] Open
Abstract
Poly (ADP-ribose) polymerase 1 (PARP1) protein is encoded by the PARP1 gene located on chromosome 1 (1q42.12) in human cells. It plays a crucial role in post-translational modification by adding poly (ADP-ribose) (PAR) groups to various proteins and PARP1 itself by utilizing nicotinamide adenine dinucleotide (NAD +) as a substrate. Since the discovery of PARP1, its role in DNA repair and cell death has been its identity. This is evident from an overwhelmingly high number of scientific reports in this regard. However, PARP1 also plays critical roles in inflammation, metabolism, tumor development and progression, chromatin modification and transcription, mRNA stability, and alternative splicing. In the present study, we attempted to compile all the scattered scientific information about this molecule, including the structure and multifunctional role of PARP1 in cancer and non-cancer diseases, along with PARP1 inhibitors (PARPis). Furthermore, for the first time, we have classified PARP1-mediated cell death for ease of understanding its role in cell death pathways.
Collapse
Affiliation(s)
- Vikas Kumar
- grid.413618.90000 0004 1767 6103Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Anurag Kumar
- grid.413618.90000 0004 1767 6103Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Khursheed Ul Islam Mir
- grid.413618.90000 0004 1767 6103Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Vandana Yadav
- grid.413618.90000 0004 1767 6103Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Shyam Singh Chauhan
- grid.413618.90000 0004 1767 6103Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
3
|
PARPs in lipid metabolism and related diseases. Prog Lipid Res 2021; 84:101117. [PMID: 34450194 DOI: 10.1016/j.plipres.2021.101117] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 08/10/2021] [Accepted: 08/18/2021] [Indexed: 12/28/2022]
Abstract
PARPs and tankyrases (TNKS) represent a family of 17 proteins. PARPs and tankyrases were originally identified as DNA repair factors, nevertheless, recent advances have shed light on their role in lipid metabolism. To date, PARP1, PARP2, PARP3, tankyrases, PARP9, PARP10, PARP14 were reported to have multi-pronged connections to lipid metabolism. The activity of PARP enzymes is fine-tuned by a set of cholesterol-based compounds as oxidized cholesterol derivatives, steroid hormones or bile acids. In turn, PARPs modulate several key processes of lipid homeostasis (lipotoxicity, fatty acid and steroid biosynthesis, lipoprotein homeostasis, fatty acid oxidation, etc.). PARPs are also cofactors of lipid-responsive nuclear receptors and transcription factors through which PARPs regulate lipid metabolism and lipid homeostasis. PARP activation often represents a disruptive signal to (lipid) metabolism, and PARP-dependent changes to lipid metabolism have pathophysiological role in the development of hyperlipidemia, obesity, alcoholic and non-alcoholic fatty liver disease, type II diabetes and its complications, atherosclerosis, cardiovascular aging and skin pathologies, just to name a few. In this synopsis we will review the evidence supporting the beneficial effects of pharmacological PARP inhibitors in these diseases/pathologies and propose repurposing PARP inhibitors already available for the treatment of various malignancies.
Collapse
|
4
|
Szabó Z, Marosvölgyi T, Szabó É, Bai P, Figler M, Verzár Z. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease. Front Physiol 2020; 11:752. [PMID: 32636763 PMCID: PMC7318894 DOI: 10.3389/fphys.2020.00752] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 06/10/2020] [Indexed: 12/15/2022] Open
Affiliation(s)
- Zoltán Szabó
- Faculty of Health Sciences, Institute of Nutritional Sciences and Dietetics, University of Pecs, Pecs, Hungary
| | - Tamás Marosvölgyi
- Medical School, Institute of Bioanalysis, University of Pecs, Pecs, Hungary
| | - Éva Szabó
- Department of Biochemistry and Medical Chemistry, Medical School, University of Pecs, Pecs, Hungary
| | - Péter Bai
- Department Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.,MTA-DE Lendület Laboratory of Cellular Metabolism, Debrecen, Hungary.,Faculty of Medicine, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary
| | - Mária Figler
- Faculty of Health Sciences, Institute of Nutritional Sciences and Dietetics, University of Pecs, Pecs, Hungary.,2nd Department of Internal Medicine and Nephrology Centre, Clinical Centre, University of Pecs, Pecs, Hungary
| | - Zsófia Verzár
- Faculty of Health Sciences, Institute of Nutritional Sciences and Dietetics, University of Pecs, Pecs, Hungary
| |
Collapse
|
5
|
The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. Genes Dev 2020; 34:321-340. [PMID: 32029456 PMCID: PMC7050491 DOI: 10.1101/gad.334284.119] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
In this review, Szanto et al. summarize the metabolic regulatory roles of PARP enzymes and their associated pathologies. Poly(ADP-ribose) polymerases (PARPs or ARTDs), originally described as DNA repair factors, have metabolic regulatory roles. PARP1, PARP2, PARP7, PARP10, and PARP14 regulate central and peripheral carbohydrate and lipid metabolism and often channel pathological disruptive metabolic signals. PARP1 and PARP2 are crucial for adipocyte differentiation, including the commitment toward white, brown, or beige adipose tissue lineages, as well as the regulation of lipid accumulation. Through regulating adipocyte function and organismal energy balance, PARPs play a role in obesity and the consequences of obesity. These findings can be translated into humans, as evidenced by studies on identical twins and SNPs affecting PARP activity.
Collapse
|
6
|
Vida A, Kardos G, Kovács T, Bodrogi BL, Bai P. Deletion of poly(ADP‑ribose) polymerase-1 changes the composition of the microbiome in the gut. Mol Med Rep 2018; 18:4335-4341. [PMID: 30221733 PMCID: PMC6172391 DOI: 10.3892/mmr.2018.9474] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 04/16/2018] [Indexed: 12/25/2022] Open
Abstract
Poly(adenosine diphosphate-ribose) polymerase (PARP)-1 is the prototypical PARP enzyme well known for its role in DNA repair and as a pro-inflammatory protein. Since PARP1 is an important co-factor of several other pro-inflammatory proteins, in the present study the possible changes in microbial flora of PARP1 knockout mice were investigated. Samples from the duodenum, cecum and feces from wild type and PARP1 knockout C57BL/6J male mice were collected and 16S ribosomal RNA genes were sequenced. Based on the sequencing results, the microbiome and compared samples throughout the lower part of the gastrointestinal system were reconstructed. The present results demonstrated that the lack of PARP1 enzyme only disturbed the microbial flora of the duodenum, where the biodiversity increased in the knockout animals on the species level but decreased on the order level. The most prominent change was the overwhelming abundance of the family Porphyromonadaceae in the duodenum of PARP1−/− animals, which disappeared in the cecum and feces where families were spread out more evenly than in the wild type animals. The findings of the present study may improve current understanding of the role of PARP1 in chronic inflammatory diseases.
Collapse
Affiliation(s)
- András Vida
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, H‑4032 Debrecen, Hungary
| | - Gábor Kardos
- Department of Microbiology, Faculty of Medicine, University of Debrecen, H‑4032 Debrecen, Hungary
| | - Tünde Kovács
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, H‑4032 Debrecen, Hungary
| | - Balázs L Bodrogi
- Department of Urology, Borsod‑Abaúj‑Zemplén County Hospital and University Teaching Hospital, H‑3525 Miskolc, Hungary
| | - Péter Bai
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, H‑4032 Debrecen, Hungary
| |
Collapse
|
7
|
Márton J, Péter M, Balogh G, Bódi B, Vida A, Szántó M, Bojcsuk D, Jankó L, Bhattoa HP, Gombos I, Uray K, Horváth I, Török Z, Balint BL, Papp Z, Vígh L, Bai P. Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator of muscular lipid homeostasis. Biochim Biophys Acta Mol Cell Biol Lipids 2018; 1863:1399-1412. [PMID: 30077797 DOI: 10.1016/j.bbalip.2018.07.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 07/22/2018] [Accepted: 07/29/2018] [Indexed: 01/11/2023]
Abstract
There is a growing body of evidence that poly(ADP-ribose) polymerase-2 (PARP2), although originally described as a DNA repair protein, has a widespread role as a metabolic regulator. We show that the ablation of PARP2 induced characteristic changes in the lipidome. The silencing of PARP2 induced the expression of sterol regulatory element-binding protein-1 and -2 and initiated de novo cholesterol biosynthesis in skeletal muscle. Increased muscular cholesterol was shunted to muscular biosynthesis of dihydrotestosterone, an anabolic steroid. Thus, skeletal muscle fibers in PARP2-/- mice were stronger compared to those of their wild-type littermates. In addition, we detected changes in the dynamics of the cell membrane, suggesting that lipidome changes also affect the biophysical characteristics of the cell membrane. In in silico and wet chemistry studies, we identified lipid species that can decrease the expression of PARP2 and potentially phenocopy the genetic abruption of PARP2, including artificial steroids. In view of these observations, we propose a new role for PARP2 as a lipid-modulated regulator of lipid metabolism.
Collapse
Affiliation(s)
- Judit Márton
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Mária Péter
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Gábor Balogh
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Beáta Bódi
- Divison of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Andras Vida
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary; MTA-DE Lendület Laboratory of Cellular Metabolism Research Group, Debrecen 4032, Hungary
| | - Magdolna Szántó
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Dora Bojcsuk
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Laura Jankó
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Harjit Pal Bhattoa
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Imre Gombos
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Karen Uray
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Ibolya Horváth
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Zsolt Török
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Balint L Balint
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032, Hungary
| | - Zoltán Papp
- Divison of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032, Hungary; HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, Debrecen 4012, Hungary
| | - László Vígh
- Biological Research Center of the Hungarian Academy of Sciences, Szeged 6726, Hungary
| | - Péter Bai
- Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Hungary; MTA-DE Lendület Laboratory of Cellular Metabolism Research Group, Debrecen 4032, Hungary; Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, 4032, Hungary.
| |
Collapse
|
8
|
Huang S, Zhang B, Chen Y, Liu H, Liu Y, Li X, Bao Z, Song Z, Wang Z. Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther 2018; 364:452-461. [PMID: 29317476 DOI: 10.1124/jpet.117.243105] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Accepted: 01/05/2018] [Indexed: 01/04/2023] Open
Abstract
Poly(ADP-ribose) polymerase (PARP) is an NAD-consuming enzyme and its specific role in the pathogenesis of alcoholic fatty liver disease (AFLD) remains elusive. In this study, we applied PJ34 [N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-acetamide hydrochloride] to inhibit hepatic PARP activity to examine the corresponding pathologic alteration in AFLD in mice and the underlying molecular mechanism. We found that PJ34 decreased the intracellular triglyceride (TG) content in hepatocytes. Moreover, PJ34 suppressed the gene expression of diglyceride acyltransferases DGAT1 and DGAT2 and elevated intracellular NAD+ levels in hepatocytes. These mechanistic observations were validated in alcohol-fed mice injected with PJ34 intraperitoneally. Our results indicate that the PJ34 injection attenuated hepatic TG accumulation in alcohol-fed mice. Furthermore, PJ34 injection lowered the gene expression of hepatic sterol regulatory element binding protein 1c, DGAT1, and DGAT2, whereas PJ34 injection augmented hepatic NAD+ levels in alcohol-fed mice. Finally, nicotinamide riboside supplementation alleviated hepatic TG accumulation in alcohol-fed mice. These data indicate that applying PARP-specific inhibitor PJ34 by intraperitoneal injection attenuated hepatic NAD+ depletion and TG accumulation in alcohol-fed mice and may be a potential candidate for use in AFLD therapy.
Collapse
Affiliation(s)
- Shishun Huang
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Bing Zhang
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Yingli Chen
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Huan Liu
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Yang Liu
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Xin Li
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Zhiwei Bao
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Zhenyuan Song
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| | - Zhigang Wang
- College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang, China (S.H., B.Z., Y.C., Y.L., X.L., Z.B., Z.W.); Fuxin Center Hospital, Fuxin, Jilin, China (H.L.); and Department of Kinesiology and Nutrition, University of Illinois, Chicago, Illinois (Z.S.)
| |
Collapse
|
9
|
Abstract
Poly(ADP-ribose) polymerase (PARP)10 is a PARP family member that performs mono-ADP-ribosylation of target proteins. Recent studies have linked PARP10 to metabolic processes and metabolic regulators that prompted us to assess whether PARP10 influences mitochondrial oxidative metabolism. The depletion of PARP10 by specific shRNAs increased mitochondrial oxidative capacity in cellular models of breast, cervical, colorectal and exocrine pancreas cancer. Upon silencing of PARP10, mitochondrial superoxide production decreased in line with increased expression of antioxidant genes pointing out lower oxidative stress upon PARP10 silencing. Improved mitochondrial oxidative capacity coincided with increased AMPK activation. The silencing of PARP10 in MCF7 and CaCo2 cells decreased the proliferation rate that correlated with increased expression of anti-Warburg enzymes (Foxo1, PGC-1α, IDH2 and fumarase). By analyzing an online database we showed that lower PARP10 expression increases survival in gastric cancer. Furthermore, PARP10 expression decreased upon fasting, a condition that is characterized by increases in mitochondrial biogenesis. Finally, lower PARP10 expression is associated with increased fatty acid oxidation.
Collapse
|
10
|
Deng Y, Liu Z, Geng Y. Anti-allergic effect of Artemisia extract in rats. Exp Ther Med 2016; 12:1130-1134. [PMID: 27446332 DOI: 10.3892/etm.2016.3361] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Accepted: 02/25/2016] [Indexed: 11/06/2022] Open
Abstract
Artemisia apiacea (also known as Artemisia annua L) is a herb commonly used in traditional Chinese medicine. In the early 1970s, artemisinin was isolated and identified as the active antimalarial ingredient, and thereafter, A. apiacea and artemisinin have been studied extensively, such as anti-inflammation and antipyresis, antibacteria, antiparasitic and immunosuppression effects of A. apiacea extract. The present study investigated the extracts anti-allergic effect obtained from the dried flowering tips of A. apiacea in rats. A systemic anaphylactic reaction model was induced in rats using compound 48/80. Artemisia extract was administered 1 h prior to the injection of compound 48/80. Artemisia was extracted from dried flowering tips of A. deserti using 80% ethanol. Subsequently, the systemic anaphylactic shock, histamine release, scratching behavior and vascular permeability induced by compound 48/80 were evaluated. The administration of Artemisia extract at 200 and 400 mg/kg doses suppressed the systemic anaphylactic shock induced by compound 48/80 in a dose-dependent manner. Overall, the Artemisia extract was able to effectively decrease systemic anaphylactic shock, histamine release, scratching behavior and vascular permeability induced by compound 48/80 in a dose-dependent manner.
Collapse
Affiliation(s)
- Yan Deng
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Zijun Liu
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Yiwei Geng
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| |
Collapse
|
11
|
Bianchi AR, Ferreri C, Ruggiero S, Deplano S, Sunda V, Galloro G, Formisano C, Mennella MRF. Automodification of PARP and fatty acid-based membrane lipidome as a promising integrated biomarker panel in molecular medicine. Biomark Med 2016; 10:229-42. [PMID: 26860237 DOI: 10.2217/bmm.16.3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIM Establishing by statistical analyses whether the analyses of auto-modified poly(ADP-ribose)polymerase and erythrocyte membrane fatty acid composition (Fat Profile(®)), separately or in tandem, help monitoring the physio-pathology of the cell, and correlate with diseases, if present. PATIENTS & METHODS Ninety five subjects were interviewed and analyzed blindly. Blood lymphocytes and erythrocytes were prepared to assay poly(ADP-ribose)polymerase automodification and fatty acid based membrane lipidome, respectively. RESULTS Poly(ADP-ribose)polymerase automodification levels confirmed their correlation with DNA damage extent, and allowed monitoring disease activity, upon surgical/therapeutic treatment. Membrane lipidome profiles showed lipid unbalance mainly linked to inflammatory states. Statistically both tests were separately significant, and correlated each other within some pathologies. CONCLUSION In the laboratory routine, both tests, separately or in tandem, might be a preliminary and helpful step to investigate the occurrence of a given disease. Their combination represents a promising integrated panel for sensible, noninvasive and routine health monitoring.
Collapse
Affiliation(s)
- Anna Rita Bianchi
- Department of Biology, University of Naples "Federico II", 80126 Naples, Italy
| | - Carla Ferreri
- National Research Council (CNR), Institute of Organic Synthesis & Photoreactivity (ISOF), 40129 Bologna, Italy
| | - Simona Ruggiero
- Department of Clinical Medicine & Surgery, University of Naples "Federico II", 80135 Naples, Italy
| | - Simone Deplano
- Lipinutragen srl, Lipidomic Laboratory, 40129 Bologna, Italy
| | - Valentina Sunda
- Lipinutragen srl, Lipidomic Laboratory, 40129 Bologna, Italy
| | - Giuseppe Galloro
- Department of Clinical Medicine & Surgery, University of Naples "Federico II", 80135 Naples, Italy
| | - Cesare Formisano
- Department of Clinical Medicine & Surgery, University of Naples "Federico II", 80135 Naples, Italy
| | - Maria Rosaria Faraone Mennella
- Department of Biology, University of Naples "Federico II", 80126 Naples, Italy.,National Institute of Biostructures & Biosystems, 00136 Rome, Italy
| |
Collapse
|
12
|
New route for the activation of poly(ADP-ribose) polymerase-1: a passage that links poly(ADP-ribose) polymerase-1 to lipotoxicity? Biochem J 2015; 469:e9-11. [PMID: 26171833 DOI: 10.1042/bj20150598] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In this issue of Biochemical Journal, Chen and colleagues characterize an interaction between ACBD3 (acyl-CoA-binding domain-containing 3) protein and PARP [poly(ADP-ribose) polymerase]-1 through the activation of ERKs (extracellular-signal-regulated kinases). This study envisages a pathway through which ABCD3 translates enhanced fatty acid levels to ERK and consequently PARP-1 activation. The consequences of PARP-1 activation lead to cellular and tissue damage, implying that the ACBD3/PARP-1 pathway is an important pathway in lipotoxicity events.
Collapse
|